2023
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosis
2018
Neutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. Journal Of The American Academy Of Dermatology 2018, 79: 987-1006. PMID: 29653210, DOI: 10.1016/j.jaad.2017.11.064.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntineoplastic AgentsAutoimmune DiseasesBehcet SyndromeChemotaxis, LeukocyteCytokinesDermisDiagnosis, DifferentialDrug EruptionsEpidermisEthnicityGenetic Predisposition to DiseaseHidradenitisHumansImmunity, InnateImmunosuppressive AgentsInflammationNeoplasmsNeutrophilsSweet SyndromeVasculitisConceptsNeutrophilic eccrine hidradenitisNeutrophilic dermatosisSweet's syndromeBehçet's diseaseInflammatory skin disorderSignificant patient morbidityUnique clinical featuresMedical education seriesSystemic corticosteroidsBiologic agentsClinical featuresNeutrophilic infiltrateCutaneous lesionsHistopathologic featuresPatient morbidityTherapeutic modalitiesNeoplastic processSkin disordersDermatosesHeterogeneous groupDiseaseDiagnosisHidradenitisDisordersSyndromeNeutrophilic dermatoses Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses
Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. Journal Of The American Academy Of Dermatology 2018, 79: 1009-1022. PMID: 29653213, DOI: 10.1016/j.jaad.2017.11.063.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory AgentsArthritisArthritis, RheumatoidDiagnosis, DifferentialDigestive System Surgical ProceduresDisease ManagementHumansImmunosuppressive AgentsInflammationInflammatory Bowel DiseasesNeutrophilsPostoperative ComplicationsPyoderma GangrenosumReoperationSkin UlcerStill's Disease, Adult-OnsetWound HealingConceptsNeutrophilic dermatosisBowel-associated dermatosis-arthritis syndromeDermatosis-arthritis syndromeRheumatoid neutrophilic dermatitisInflammatory skin disorderSignificant patient morbidityUnique clinical featuresMedical education seriesNeutrophilic dermatitisSystemic corticosteroidsPyoderma gangrenosumClinical characteristicsBiologic agentsClinical featuresNeutrophilic infiltrateCutaneous lesionsHistopathologic featuresPatient morbidityTherapeutic modalitiesNeoplastic processSkin disordersDermatosesHeterogeneous groupDiagnosisGangrenosum